ClinicalTrials.gg
CompletedNCT03610633Updated Oct 23, 2019Results posted

Oxytocin and Stress Response in Alcohol Use Disorder

A Phase 2 interventional study of Oxytocin and Placebo in Alcohol Use Disorder, sponsored by Medical University of South Carolina. Completed at 1 site in United States. Open to participants aged 21 Years to 40 Years. Per ClinicalTrials.gov, last updated 2019-10-23.

Sponsored by Medical University of South Carolina · Phase 2, Interventional, and Treatment

Phase
Phase 2
Study type
Interventional
Enrollment
11
Allocation
Randomized
Ages
21 Years to 40 Years
Sex
All
01

Study summary

Individuals with alcohol use disorder (AUD) will complete one functional Magnetic Resonance Imaging (fMRI) scanning visit. Prior to the scan, individuals will receive a nasal spray of either 24 international units (IU) of oxytocin (OT), or placebo (PBO). During the scan, they will perform the Montreal Imaging Stress Task (MIST), a social stress task. Subjective craving and anxiety data will be collected.

Read the detailed description

Participants: Twenty-four individuals with AUD will be recruited through the Clinical Intake and Assessment (CIA) Core of the Alcohol Research Center (ARC). Screening and basic assessments will be conducted by the CIA Core to determine eligibility and suitability for participation in this pilot project. Each individual will sign an Institutional Review Board (IRB)-approved informed consent form.

Study Visit Assessments: The Drinking Motives Questionnaire Revised will be used to assess motivation for drinking across four subscales: (1) coping motives; (2) social motives; (3) conformity motives; and (4) enhancement motives. The Form 90 will be used to assess daily alcohol consumption in the 90 days prior to the study visit and the time from last drink . A modification of the Within Session Rating Scale will be used to assess craving and mood.

Study Visit Procedures: Participants will be asked to arrive at the Addiction Sciences Division on the study visit day. Female participants will have their urine tested for pregnancy. Females who test positive for pregnancy will be excluded. All participants will be tested for drugs of abuse and alcohol. Patients testing positive for drugs, with the exception of marijuana, will be excluded; patients testing positive for alcohol may be re-scheduled. Participants will be asked about substance use in the last 90 days and will fill out the Drinking Motives Questionnaire. Subjects who have not had a research physical exam within the last 30 days will have a physical completed. They will then be escorted to the scanner at 30 Bee Street.

The study will use a double-blind placebo controlled design. Intranasal OT (n=12) or PBO (n=12) sprays will be administered at 11:30 am, approximately 45 min prior to the scanning session. This dose and timing of OT administration were selected based on the literature.

MIST Procedure: The study will use a block design of three, 6-min runs separated by 2-min of rest for feedback, for a total of 24 min. During each run, participants will be exposed to 40-sec blocks of three different conditions (rest, control, and experimental). Prior to the task, participants will are shown images of what the screen will look like during each condition. The participants will be instructed to relax during the rest condition and focus on the screen. During the control condition, the participants will be asked to answer math problems as accurately as possible but will also be told that their responses will not be recorded. During the experimental condition, the participants will be asked to perform the math task as quickly and accurately as possible. A performance bar located on the screen will allow them to see their performance as compared to an "average" person. The participants will be told that the average person would answer about 85% of the problems correctly; however, the program limits the participants' performance rate to between 35-45%. A time limit will be enforced throughout the experimental condition. After each run, the participants will be given negative feedback from the investigator.

Blood Oxygen Level Dependent (BOLD)-fMRI Procedure: Data will be acquired on a Siemens Trio 3T scanner in MUSC's Center for Biomedical Imaging. For co-registration and normalization of functional images, a high resolution T1-weighted Magnetization-Prepared Rapid Acquisition with Gradient Echo (MPRAGE) anatomical image will be acquired with the following parameters: Time of Repetition (TR)= 2100 ms, Echo Time (TE)= 4.18 ms, flip angle= 12°, field of view= 256 mm, slice thickness= 1.0 mm. The scanning planes will be oriented parallel to the anterior commissure-posterior commissure line. Participants will be asked to relax and keep their eyes opened and fixed on a cross-hair for 6 min while resting state data are collected. Participants will then complete the MIST. T2*-weighted gradient-echo planar images (EPI) will be acquired with the following parameters: TR= 2000 ms, TE= 27 ms, flip angle= 76º, matrix 64 x 64, field of view= 23 cm, slice thickness= 3.7 mm with no gap, with 36 slices to cover the entire brain.

02

Conditions studied

  • Alcohol Use Disorder

Browse trials for

03

In context

Alcoholism

1,634 studies on the registry are indexed under Alcoholism; 329 are open to participants now.

This study's enrollment of 11 is below the median of 88 across 1,395 interventional studies indexed under Alcoholism.

Browse Alcoholism studies →

Lead sponsor

Medical University of South Carolina is the lead sponsor of 871 studies on the registry; 163 are open to participants now.

Of its 131 completed or terminated interventional studies of FDA-regulated products, 104 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 21-40.
  2. Subjects must be able to provide informed consent and function at an intellectual level sufficient to allow accurate completion of all assessment instruments.
  3. Meets the DSM 5 criteria for current alcohol use disorder.
  4. Reports drinking on average, at least 20 standard alcoholic drinks per week for at least the past three months.
  5. Currently not engaged in, and does not want treatment for, alcohol related problems.
  6. Lives within 50 miles of the study site.
  7. Subjects must consent to random assignment.
  8. Able to maintain abstinence for two days (without the aid of detoxification medications) as determined by self report and breathalyzer measurements Subjects must also have a negative breathalyzer urine drug screen at the study visit.
  9. Subjects must consent to the study visit which includes an outpatient admission to the Addiction Sciences Division and completing one functional magnetic resonance imaging (fMRI) scanning session.

Exclusion criteria

Exclusion Criteria:

  1. Currently meets DSM 5 criteria for any other psychoactive substance use disorder.
  2. Is determined
  3. Any psychoactive substance use (except marijuana and nicotine) within the last 30 days by self-report and urine drug screen. For marijuana, no use within the last seven days by verbal report and negative (or decreasing) urine THC levels.
  4. Meets DSM 5 criteria for current major depression, panic disorder, obsessive-compulsive disorder, post traumatic stress syndrome, bipolar affective disorder, schizophrenia, dissociate disorders, eating disorders, and any other psychotic disorder or organic mental disorder.
  5. Has current suicidal ideation or homicidal ideation.
  6. Has the need for maintenance or acute treatment with any psychoactive medication including anti-seizure medications and medications for ADHD.
  7. Is currently taking medication known to affect alcohol intake (e.g., disulfiram, naltrexone, acamprosate, topiramate).
  8. Has clinically significant medical problems such as cardiovascular, renal, GI, neurological (e.g. seizure disorder) or endocrine problems that would impair participation or limit medication ingestion.
  9. Has past history of alcohol related medical illness such as gastrointestinal bleeding, pancreatitis, peptic ulcer, hepatic cirrhosis or alcoholic hepatitis.
  10. Has hepatocellular disease indicated by elevations of SGPT (ALT) or SGOT (AST) greater than 2.5 times normal at screening.
  11. Females of childbearing potential who are pregnant (by urine HCG), nursing, or who are not using a reliable form of birth control.
  12. Has current charges pending for a violent crime (not including DUI related offenses).
  13. Does not have a stable living situation.
  14. Presence of ferrous metal in the body, as evidence by metal screening and self-report.
  15. Severe claustrophobia or morbid obesity that preclude placement in the MRI scanner.
  16. History of head injury with >2 minutes of unconsciousness.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    Oxytocin/alcohol use disorder

    Participants will receive 24 IU of oxytocin prior to completing fMRI scanning procedures.

    Drug: Oxytocin

  • Placebo comparator
    Placebo/Alcohol use disorder

    Participants will receive placebo (saline solution) prior to completing fMRI scanning procedures.

    Drug: Placebo

Interventions

  • The neuropeptide oxytocin (OT) increases social approach, trust, and reduces anxiety to social stress.

    Also known as: Pitocin

  • DrugPlacebo

    Saline solution.

06

What researchers measure

Primary outcomes

  1. Corticolimbic Functional Connectivity Based on fMRI Blood Oxygenation Level Dependent (BOLD) Response During the Stress Versus Neutral Conditions of the Montreal Imaging Stress Test Task Averaged Over the Second and Third Functional Runs

    Corticolimbic functional connectivity will be determined using psychophysiological interaction (PPI) modeling. The left and right amygdala will serve as seed regions. Connectivity of each seed region with the homologous orbitofrontal cortex region will be represented as a parameter estimate, yielding one parameter estimate for right amygdala-right orbitofrontal connectivity and one parameter estimate for left amygdala-left orbitofrontal connectivity per subject.

    Time frame: 60 minutes following medication (oxytocin or placebo)

07

Results

Posted Oct 23, 2019

Participant flow

Participant flow — Overall Study
MilestoneOxytocin/Alcohol Use DisorderPlacebo/Alcohol Use Disorder
Started56
Completed55
Not completed01

Outcome measures

PrimaryCorticolimbic Functional Connectivity Based on fMRI Blood Oxygenation Level Dependent (BOLD) Response During the Stress Versus Neutral Conditions of the Montreal Imaging Stress Test Task Averaged Over the Second and Third Functional Runs

Corticolimbic functional connectivity will be determined using psychophysiological interaction (PPI) modeling. The left and right amygdala will serve as seed regions. Connectivity of each seed region with the homologous orbitofrontal cortex region will be represented as a parameter estimate, yielding one parameter estimate for right amygdala-right orbitofrontal connectivity and one parameter estimate for left amygdala-left orbitofrontal connectivity per subject.

Time frame:
60 minutes following medication (oxytocin or placebo)
Reported as:
Mean · contrast of parameter estimates
Corticolimbic Functional Connectivity Based on fMRI Blood Oxygenation Level Dependent (BOLD) Response During the Stress Versus Neutral Conditions of the Montreal Imaging Stress Test Task Averaged Over the Second and Third Functional Runs
contrast of parameter estimatesOxytocin/Alcohol Use DisorderPlacebo/Alcohol Use Disorder
Left amygdala left orbitofrontal connectivity-.12723 ± .103532-.04836 ± .150718
Right amygdala right orbitofrontal connectivity.042561 ± .155865-.06624 ± .240009

Adverse events

Collected over 6 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Oxytocin/Alcohol Use Disorder0/5 (0%)0/5 (0%)0/5 (0%)
Placebo/Alcohol Use Disorder0/5 (0%)0/5 (0%)0/5 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Oxytocin/Alcohol Use DisorderPlacebo/Alcohol Use DisorderTotal
<=18 years000
Between 18 and 65 years5510
>=65 years000
Age, Continuous
Age, Continuous(years)Oxytocin/Alcohol Use DisorderPlacebo/Alcohol Use DisorderTotal
Mean25.2 (22 to 28)24 (22 to 27)24.6 (22 to 28)
Sex: Female, Male
Sex: Female, Male(Participants)Oxytocin/Alcohol Use DisorderPlacebo/Alcohol Use DisorderTotal
Female123
Male437
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Oxytocin/Alcohol Use DisorderPlacebo/Alcohol Use DisorderTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American101
White459
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Oxytocin/Alcohol Use DisorderPlacebo/Alcohol Use DisorderTotal
United States5510
08

Study locations

1 site
  • Addiction Sciences Division-Medical University of South Carolina
    Charleston, South Carolina 29403, United States
09

References and documents

Study documents

  • Protocol and statistical analysis plan · Jan 4, 2018

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2016, a primary completion of Sep 2018 and a completion of Sep 2018. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2019, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2016
First posted
Aug 1, 2018
Start
Mar 2016
Primary completionActual
Sep 2018
CompletionActual
Sep 2018
Results first posted
Oct 23, 2019
Last update
Oct 23, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 23, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03610633
Responsible party
Sponsor
First posted
Aug 1, 2018
Start date
Mar 2016
Primary completion
Sep 2018
Completion
Sep 2018
Results posted
Oct 23, 2019
Last update
Oct 23, 2019

Study contacts

Jane Joseph, PhD
principal investigator · Medical University of South Carolina

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Oxytocin

Start the discussion